Pfizer Canada is contributing $4.5 million to a fund that will support the creation of a consortium of Quebec-based researchers for Alzheimer's disease and support high-risk, high-spinoff projects. The funding goes to the Fonds de recherche du Québec - Santé which will manage the Pfizer-FRQS Innovation Fund for Alzheimer's Disease and Related Disorders. Among its intended outcomes are an Alzheimer's patient data registry and a better understanding of the mechanisms underlying the disease by exploring research hypotheses that have never been tested. Details will be announced later this month on the FRQS website (www.frqs.gouv.qc.ca)....